Your browser doesn't support javascript.
loading
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
Heisen, M; Treur, M J; van der Hel, W S; Frequin, S T F M; Groot, M T; Verheggen, B G.
Affiliation
  • Heisen M; Pharmerit Europe, Rotterdam, The Netherlands. mheisen@pharmerit.com
J Med Econ ; 15(6): 1149-58, 2012.
Article in En | MEDLINE | ID: mdl-22737996
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propylene Glycols / Sphingosine / Cost Savings / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Health Services / Immunosuppressive Agents Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Determinantes_sociais_saude Limits: Humans Country/Region as subject: Europa Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2012 Document type: Article Affiliation country: Países Bajos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propylene Glycols / Sphingosine / Cost Savings / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Health Services / Immunosuppressive Agents Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Determinantes_sociais_saude Limits: Humans Country/Region as subject: Europa Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2012 Document type: Article Affiliation country: Países Bajos Country of publication: Reino Unido